C12Y 301/04053
3',5'-cyclic-amp phosphodiesterase
Official title: 3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
C12Y301/04053 (3',5'-cyclic-amp phosphodiesterase) appears on 8 US grants and 12 published applications in this corpus.
Search patents in C12Y- Granted patents
- 8
- Published applications
- 12
- Assignees
- 10
- Inventors
- 28
- Latest grant
- 29 Jun 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 1 | 1 |
| 2018 | 1 | 4 |
| 2019 | 1 | 0 |
| 2020 | 2 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating COPD and other inflammatory conditions29 Jun 2021US 11,045,456 B2Georgia State University Research Foundation, Inc.
- Triazole derivatives and their use as PDE4 activators6 Oct 2020US 10,793,531 B2Mironid Limited
- T cells with increased immunosuppression resistance23 Jun 2020US 10,689,620 B2Adaptimmune Limited
- Triazole derivatives and their use as PDE4 activators20 Aug 2019US 10,385,027 B2Mironid Limited
- T cells with increased immunosuppression resistance22 May 2018US 9,976,121 B2Adaptimmune Limited
- Pde enhanced car-t cells25 Jun 2026US 2026/0174851 A1Koninklijke Philips N. V.
- Microbial cell factories producing vitamin b compounds7 Nov 2024US 2024/0368659 A1
- Methods of Treating Epilepsy via Phosphodiesterase 4 (PDE4) Inhibition31 Mar 2022US 2022/0098257 A1Path Therapeutics, Inc.
- Targeting of makap-pde4d3 complexes in neurodegenerative disease10 Feb 2022US 2022/0041667 A1The United States Government as represented by the Department of Veterans Affairs
- Triazole derivatives and their use as pde4 activators2 Jan 2020US 2020/0002296 A1Mironid Limited
Most cited
By later US patents
- T cells with increased immunosuppression resistance3US 9,976,121 B2Adaptimmune Limited · 2018
- Triazole derivatives and their use as PDE4 activators2US 10,385,027 B2Mironid Limited · 2019
- Triazole derivatives and their use as PDE4 activators1US 10,793,531 B2Mironid Limited · 2020
- RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders1US 8,673,873 B1Alcon Research, Ltd. · 2014
- RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders1US 9,453,220 B2Arrowhead Pharmaceuticals, Inc. · 2016